This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Sat Jun 13, 2:20PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Biogen (BIIB) with bullish sentiments.

Introducing TipRanks MCP for Agents

Dianthus Therapeutics (DNTH)

In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on Dianthus Therapeutics. The company’s shares closed last Friday at $82.74.

According to TipRanks.com, Deschner is a 5-star analyst with an average return of 37.3% and a 63.5% success rate. Deschner covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Liquidia Technologies, and Vera Therapeutics. ;'>

Currently, the analyst consensus on Dianthus Therapeutics is a Strong Buy with an average price target of $130.00, implying a 67.9% upside from current levels. In a report issued on June 10, William Blair also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Biogen (BIIB)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Biogen, with a price target of $221.00. The company’s shares closed last Friday at $199.92.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -1.5% and a 42.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Maze Therapeutics, Inc., Syndax Pharmaceuticals, and Atara Biotherapeutics. ;'>

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $221.14, implying a 10.3% upside from current levels. In a report issued on June 8, Needham also upgraded the stock to Buy with a $255.00 price target.

Read More on DNTH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.